Chief Executive Officer
Adi Mohanty is an experienced biotech business leader with a track record of successful product development and approval followed by rapid commercialization. Previously, he served as CEO of BioTime, where during his tenure, the company advanced its platform science to develop product candidates from the lab into mid- and late-stage clinical trials and unlocked value through strategic transactions, resulting in a better-capitalized company, poised to build substantial value for shareholders through renewed focus on clinical progress.
Adi formerly served as vice president at Transkaryotic Therapies, which was acquired by Shire PLC. Throughout a decade at Shire, he held several executive positions spanning global technical operations, product development, and commercial operations, culminating in the role of President, Regenerative Medicine. Earlier in his career, he held a variety of management positions in the bioscience division of Baxter Healthcare. Additionally, he has served as a board member for OncoCyte, a diagnostics company that he helped take public. Mr. Mohanty received his MBA at Saint Mary’s College, California. He also holds a Master of Science in Chemical Engineering from Clarkson University.